Advanced Filters
noise

Hot Flash Clinical Trials

A listing of Hot Flash medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 364 clinical trials

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Systemic Lupus Erythematosus

18 - 75 years of age All Phase 1
Q Qiubai Li, Professor

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

A clinical study to explore the safety, efficacy and cell metabolic kinetics of universal CD19/20 car-t cell injection in moderate to severe refractory systemic lupus erythematosus. This study is a single arm, open, exploratory dose increasing clinical study, which aims to evaluate the safety, efficacy and cell metabolic dynamics of …

18 - 60 years of age All Phase 1
D Dan LIPSKER, MD, PhD

Panniculitis in Dermatomyositis

Adipose tissue involvement is rare in dermatomyositis. The occurrence of partial or diffuse lipodystrophy is a rare but well-characterized manifestation, particularly in juvenile forms of dermatomyositis. Panniculitis, on the other hand, is exceptional and rarely described in the literature, mostly in the form of clinical cases. Panniculitis in dermatomyositis is …

1 years of age All Phase N/A

Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE

This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous BCMA/CD70-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.

18 years of age All Phase 1
C Chrisanna Dobrowolski, MD

Alnuctamab for Refractory SLE (LATTE Study)

This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care treatments.

18 - 60 years of age All Phase 1
M Mengtao Li, Doctor

The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

This study will evaluate the effect and safety of 626 in patients with SLE

18 - 70 years of age All Phase 1/2
l lei liu

A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

A Phase I, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study of Single Subcutaneous Injections of LBL-047 in Healthy Adults and Patients with systemic lupus erythematosus.

18 - 60 years of age All Phase 1

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous CD19-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.

18 years of age All Phase 1
A Andras Perl, M.D., Ph.D.

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. We previously discovered the depletion of glutathione in lymphocytes of patients with SLE and associated this metabolic change …

18 years of age All Phase 2
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

Study Description: Systemic lupus erythematosus (SLE) occurs predominantly in women and is driven by type I interferon dysregulation and neutrophil hyperresponsiveness. Neutrophils in females have reduced mitochondrial bioenergetic capacity which affects immunometabolism. Nicotinamide adenine dinucleotide (NAD)+ boosting with nicotinamide riboside blunts type 1 IFN activation in-vivo in monocytes of healthy …

18 - 120 years of age Female Phase 1/2

Simplify language using AI